This systematic review and meta-analysis examined algorithm-guided treatments (AGTs) versus treatment as usual (TAU) for adult patients with major depressive disorder. The analysis included 7 randomized controlled trials with over 3,500 total participants. The review found that most studies demonstrated superior outcomes for AGT, though specific effect sizes, absolute event rates, and statistical measures for significance were not reported.
For key outcomes, AGT was associated with a significantly shorter time to remission and higher proportions of patients achieving both remission and response compared to TAU. Adherence to treatment protocols was also reported to be better with AGT. However, in populations with comorbid conditions, differences between AGT and TAU were marginal or nonsignificant.
No safety, tolerability, or adverse event data were reported in the available evidence. Key limitations include the lack of reported primary outcome definition, specific statistical measures, and absolute numbers for all outcomes. The funding sources and potential conflicts of interest were also not reported.
The findings cautiously support the wider integration of structured, algorithm-based treatment strategies into clinical practice for major depressive disorder. However, clinicians should interpret these results with caution due to the incomplete reporting of critical data points and the variable findings in comorbid populations.
View Original Abstract ↓
IntroductionA substantial proportion of patients with major depressive disorder do not remit after the initial pharmacological treatment, and a major obstacle is that progression to subsequent treatment steps often occurs too slowly, highlighting the need for more structured and effective therapeutic strategies. Algorithm-guided treatments (AGTs) provide a systematic, stepwise framework for clinical decision-making, potentially improving acute treatment outcomes compared to treatment as usual (TAU).MethodsThis systematic review, conducted according to PRISMA 2020 guidelines, evaluated randomized controlled trials (RCTs) comparing AGTs to TAU in adult patients with major depressive disorder. Databases searched included PubMed, Scopus, Embase, PsychInfo, and the Cochrane Library up to June 2025. Trials investigating adults diagnosed with major depressive disorder, utilizing clinician-rated depression scales, and with a trial duration of four weeks or more were included.ResultsSeven RCTs met the criteria, encompassing over 3,500 participants. Most studies demonstrated superior outcomes in participants allocated to AGT compared to TAU, including significantly shorter time to remission, a higher proportion of patients achieving remission and response, as well as better adherence to treatment protocols. Some studies found marginal or nonsignificant differences between interventions in some of the outcomes, particularly those involving comorbid populations.DiscussionThese findings suggest that implementing structured, algorithm-based treatment strategies can improve the quality and efficacy of care for patients diagnosed with major depressive disorder, supporting their wider integration into clinical practice.